Adocia’s BioChaperone(R) is a library of polysaccharides modified with naturally occurring molecules. These polymers are designed to form a reversible molecular complex with therapeutic proteins in order to solubilize and stabilize these proteins and to control their delivery.
“Adocia has exciting opportunities to present to the scientific and medical communities the results obtained with the combination of BioChaperone and therapeutic proteins, and the potential of this system for protein formulation in general,” said Dr Gérard Soula, Adocia’s president and CEO.
Two BioChaperone products have proven their safety and efficacy in clinical trials.
The first is a new treatment for diabetic foot ulcers and consists of a combination of BioChaperone and Platelet Derived Growth Factor, rhPDGF-BB. BioChaperone PDGF-BB is currently being evaluated against Regranex(R) (beclapermin gel, Systagenix) in a large phase II clinical trial in India. The study objective is to demonstrate the non-inferiority of BioChaperone PDGF-BB, applied once every two days, versus Regranex applied every day on percentage of complete wound closure after 20 weeks. Interim analysis demonstrates the non-inferiority of BioChaperone PDGF-BB compared to Regranex even at a dose three times lower.
The second is an innovative fast-acting human insulin product for the postprandial glycemic control of diabetics. BioChaperone human insulin has been evaluated in a phase I clinical trial against a commercial fast-acting analog, NovoLog(R) (Novo Nordisk) and a regular human insulin, Actrapid(R) (Novo Nordisk) on 12 healthy volunteers in Germany. The results of this study demonstrate that BioChaperone human insulin acts as fast as NovoLog(R) in the regulation of glycemia. These results have been disclosed in a previous press release (15th March 2011).
Other promising results on the formulation of monoclonal antibodies with BioChaperone will be presented during these conferences.
2nd Annual Protein Formulation Development Forum
June 15 – 17, 2011
Location: Hotel Avenida Palace - Barcelona, Spain
71st Scientific Sessions of the American Diabetes Association (2011)
June 24 – 28, 2011
Location: San Diego Convention Center - San Diego, California
38th Annual Meeting & Exposition of the Controlled Release Society
July 30, 2011
Location: Gaylord National Hotel and Convention Center - National Harbor, Maryland, U.S.A.
“The present results illustrate the large potential and versatility of BioChaperone to improve the efficacy of three different classes of proteins from small size proteins such as insulin, middle size proteins such as PDGF-BB, to large size proteins such as monoclonal antibodies,” said Dr Olivier Soula, Adocia’s vice-president and R&D director.
About Adocia SAS (www.adocia.com)
Adocia (Lyon, France) is a privately held French biotechnology company specialized in regenerative medicine and in the treatment of chronic diseases. Adocia is developing innovative protein formulations based on its proprietary technology, BioChaperone. Adocia is engaged in two collaborative programs on the formulation of monoclonal antibodies using its BioChaperone(R) platform with two biopharma companies, and it has two collaborations with medtech companies.
Since its inception, Adocia has raised EUR 28 million in two financing rounds.
Mark Tidmarsh
ANDREW LLOYD & ASSOCIATES
http://www.ala.com
mark@ala.com
Brighton Business Centre 95 Ditchling Road Brighton BN1 4ST ENGLAND
Tel: +44 1273 675100
Fax: +44 1273 675400
55 rue Boissonade 75014 Paris FRANCE
Tel: +33 1 56 54 07 00
Fax: +33 1 56 54 07 01
INTERNATIONAL TECHNOLOGY MARKETS, STRATEGY & COMMUNICATION
